argenex (ARGX) Stock Forecast & Price Target

$851.29 -5.65 (-0.66%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$850.95 -0.34 (-0.04%)

As of 08/14/2026 07:34 PM Eastern

Compare

argenex - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 24 Analyst Ratings

Sell
0

Hold
4

Buy
20

Based on 24 Wall Street analysts who have issued ratings for argenex in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 24 analysts, 4 have given a hold rating, 18 have given a buy rating, and 2 have given a strong buy rating for ARGX.

Consensus Price Target

$1,056.89
24.15% Upside

According to the 24 analysts' twelve-month price targets for argenex, the average price target is $1,056.89. The highest price target for ARGX is $1,291.00, while the lowest price target for ARGX is $818.00. The average price target represents a forecasted upside of 24.15% from the current price of $851.29.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for ARGX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for argenex and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ARGX Analyst Ratings Over Time

Type	Current Forecast 8/15/25 to 8/15/26	1 Month Ago 7/16/25 to 7/16/26	3 Months Ago 5/17/25 to 5/17/26	1 Year Ago 8/15/24 to 8/15/25
Strong Buy	2 Strong Buy rating(s)	2 Strong Buy rating(s)	2 Strong Buy rating(s)	2 Strong Buy rating(s)
Buy	18 Buy rating(s)	18 Buy rating(s)	18 Buy rating(s)	17 Buy rating(s)
Hold	4 Hold rating(s)	4 Hold rating(s)	4 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$1,056.89	$1,037.61	$1,017.78	$746.81
Forecasted Upside	24.15% Upside	20.94% Upside	27.33% Upside	14.22% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Buy

ARGX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ARGX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

argenex Stock vs. The Competition

Type	argenex	Healthcare Companies	Broader Market
Consensus Rating Score	2.92	2.30	2.53
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	24.15% Upside	785.25% Upside	11.05% Upside
News Sentiment Rating	Positive News See Recent ARGX News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
8/4/2026	Guggenheim 5 of 5 stars	Yatin Suneja 5 of 5 stars	Initiated Coverage	Buy	$1,185.00	+40.36%
7/28/2026	Wedbush 5 of 5 stars	David Nierengarten 5 of 5 stars	Boost Target	Outperform	$1,000.00 ➝ $1,050.00	+18.13%
7/27/2026	Robert W. Baird 3 of 5 stars	Colleen Kusy Not Rated	Boost Target	Neutral	$867.00 ➝ $932.00	+1.50%
7/24/2026	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Leland Gershell Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$1,014.00 ➝ $1,037.00	+13.55%
7/24/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Luca Issi Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$945.00 ➝ $1,025.00	+11.47%
7/24/2026	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jason N. Butler Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Market Outperform	$944.00 ➝ $932.00	+0.80%
7/23/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Hold (C+) ➝ Hold (C)
7/21/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Samantha Semenkow Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$1,152.00 ➝ $1,182.00	+35.70%
7/2/2026	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Tazeen Ahmad Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$1,016.00 ➝ $1,088.00	+14.60%
6/25/2026	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Douglas Tsao Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$940.00	+10.26%
Get the Latest News and Ratings for ARGX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for argenex and its competitors with MarketBeat's FREE daily newsletter.
6/24/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matthew Harrison Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$1,170.00 ➝ $1,180.00	+38.27%
6/1/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Derek Archila Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$1,260.00 ➝ $1,291.00	+55.71%
4/3/2026	Glj Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Strong-Buy
3/10/2026	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold ➝ Buy
2/20/2026	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Strong Sell ➝ Hold
1/8/2026	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joon Lee Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$950.00 ➝ $1,030.00	+27.73%
12/19/2025	DZ Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Strong-Buy
12/11/2025	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Alex Thompson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$1,028.00 ➝ $1,248.00	+40.21%
12/8/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	James Gordon Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$925.00 ➝ $1,100.00	+20.76%
11/24/2025	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Andy Chen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform ➝ Peer Perform
11/4/2025	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Allison Bratzel Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$820.00 ➝ $930.00	+10.42%
10/31/2025	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Yaron Werber Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$800.00 ➝ $1,146.00	+41.49%
10/31/2025	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Gavin Clark-Gartner Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$775.00 ➝ $910.00	+10.93%
8/26/2025	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target	Buy	$818.00	+16.11%
3/17/2025	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	J. Smith Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform
2/28/2025	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Myles Minter Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform
11/5/2024	Scotiabank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	George Farmer Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Sector Perform ➝ Sector Outperform	$439.00 ➝ $715.00	+21.46%
10/10/2024	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Danielle Brill Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$605.00	+16.23%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 02:22 PM ET.

Should I Buy argenex Stock? ARGX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, August 10, 2026. Please send any questions or comments about these argenex pros and cons to contact@marketbeat.com.

argenex
Bull Case

Here are some ways that investors could benefit from investing in argenx SE:

The current stock price is around $868, reflecting strong market interest and potential for growth.
argenx SE reported impressive earnings per share of $7.32, significantly exceeding analyst expectations, indicating robust financial performance.
The company has a high return on equity, showcasing effective management and profitability, which can attract investors looking for strong returns.
With a market capitalization of approximately $57.44 billion, argenx SE is positioned as a major player in the biotechnology sector, suggesting stability and growth potential.
The lead product, efgartigimod (Vyvgart), is a promising treatment for IgG-mediated disorders, addressing significant unmet medical needs and potentially driving future revenue growth.

argenex
Bear Case

Investors should be bearish about investing in argenx SE for these reasons:

The stock has a relatively high price-to-earnings ratio, which may indicate that it is overvalued compared to its earnings, posing a risk for new investors.
Despite strong earnings, the company faces competition in the biotechnology field, which could impact its market share and profitability in the future.
The beta of 0.45 suggests lower volatility compared to the market, which may not appeal to investors seeking high-risk, high-reward opportunities.
Analysts predict earnings per share for the current year to be around 26.27, which may indicate a slowdown in growth compared to previous periods.
As a biotechnology firm, argenx SE is subject to regulatory risks that could affect product approvals and market entry, adding uncertainty to its future performance.

ARGX Forecast - Frequently Asked Questions

According to the research reports of 24 Wall Street equities research analysts, the average twelve-month stock price forecast for argenex is $1,056.89, with a high forecast of $1,291.00 and a low forecast of $818.00.

24 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for argenex in the last twelve months. There are currently 4 hold ratings, 18 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ARGX shares.

According to analysts, argenex's stock has a predicted upside of 24.15% based on their 12-month stock forecasts.

Over the previous 90 days, argenex's stock had 1 upgrade and 1 downgrade by analysts.

argenex has been rated by research analysts at Bank of America, Citigroup, Citizens Jmp, Guggenheim, HC Wainwright, Morgan Stanley, Oppenheimer, Robert W. Baird, Royal Bank Of Canada, Wedbush, Weiss Ratings, and Wells Fargo & Company in the past 90 days.

Analysts like argenex more than other "healthcare" companies. The consensus rating for argenex is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how ARGX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With argenex Recommendations

This page (NASDAQ:ARGX) was last updated on 8/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

argenex (ARGX) Stock Forecast & Price Target